ARTICLE | Clinical News
Intra-Cellular begins Phase III trial of ITI-214 in PD
December 1, 2017 9:39 PM UTC
In October, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) began the Phase I/II ITI-214-105 trial of ITI-214 to treat idiopathic Parkinson's disease.
The double-blind, U.S. trial will evaluate once-daily oral doses of 1, 3 or 10 mg ITI-214 in about 24 PD patients for 7 days vs. placebo. The primary endpoint is safety and the secondary endpoints will assess pharmacokinetics...
BCIQ Company Profiles
BCIQ Target Profiles